China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple partnerships with compatriot firm Elpiscience Biopharmaceuticals Inc. WuXi Bio will be involved in Elpiscience’s process development and pilot test facilities in Suzhou, facilitating their transformation into a top-tier macromolecule development and GMP compliant service base. Additionally, WuXi Bio will become Elpiscience’s exclusive CDMO partner. Financial details of the partnership were not disclosed.
Partnership Scope and Objectives
Elpiscience, a Shanghai-based biotech firm, focuses on developing products targeted against innate immunity and/or capable of tumor microenvironment regulation. The company combines in-house discovery with partnered products to advance its pipeline. WuXi Bio, with its extensive business presence across China, the US, Ireland, Germany, and Singapore, will leverage its expertise to support Elpiscience’s development initiatives. As of June 2022, WuXi Bio has assisted clients with 534 projects, including 14 commercialization projects, highlighting its robust capabilities in the biologics sector.
Future Outlook
The strategic partnership between WuXi Biologics and Elpiscience marks a significant step in enhancing the development and commercialization of innovative biologics. By combining Elpiscience’s focus on innate immunity and tumor microenvironment regulation with WuXi Bio’s global capabilities, the collaboration aims to drive innovation and improve patient outcomes in oncology and related fields.-Fineline Info & Tech
